Kymera Therapeutics Ownership 2024 | Who Owns Kymera Therapeutics Now?
Institutional Ownership
35.92%
Insider Ownership
1.28%
Retail Ownership
62.79%
Institutional Holders
89.00
Kymera Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 9.03% | 0.02% | 6,390,658 | 58,646 | 0.93% | 190,763,000 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 8.47% | 2.29% | 5,995,928 | - | - | 178,978,451 | Jun 30, 2024 |
| ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 7.56% | 16.82% | 5,350,422 | -26,940 | -0.50% | 159,710,097 | Jun 30, 2024 |
| BVF INC/IL | 7.29% | 4.32% | 5,161,801 | - | - | 154,079,760 | Jun 30, 2024 |
| FMR LLC | 6.82% | 0.01% | 4,826,840 | 462,430 | 10.60% | 144,081,174 | Jun 30, 2024 |
| VANGUARD GROUP INC | 6.81% | 0.00% | 4,822,416 | 55,366 | 1.16% | 143,949,118 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.09% | 0.02% | 4,309,405 | 15,708 | 0.37% | 128,635,739 | Jun 30, 2024 |
| BLACKROCK INC. | 5.87% | 0.00% | 4,155,429 | 499,769 | 13.67% | 124,039,557 | Jun 30, 2024 |
| AVORO CAPITAL ADVISORS LLC | 5.50% | 1.55% | 3,888,888 | - | - | 116,083,307 | Jun 30, 2024 |
| ARTAL GROUP S.A. | 4.25% | 2.29% | 3,005,610 | -21,525 | -0.71% | 89,717,459 | Jun 30, 2024 |
| STATE STREET CORP | 2.70% | 0.00% | 1,910,691 | -761,827 | -28.51% | 57,034,126,000 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 2.23% | 2.85% | 1,579,275 | -154,814 | -8.93% | 47,141,359 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 2.12% | 1.34% | 1,500,000 | 237,754 | 18.84% | 44,775,000 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.64% | 1.05% | 1,163,973 | -358,265 | -23.54% | 34,744,594 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.49% | 0.00% | 1,054,220 | 88,520 | 9.17% | 31,474,663 | Jun 30, 2024 |
| MORGAN STANLEY | 0.89% | 0.00% | 631,738 | 84,598 | 15.46% | 18,857,400 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.73% | 0.15% | 517,797 | 16,867 | 3.37% | 15,456,240 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.65% | 0.00% | 462,309 | 11,791 | 2.62% | 13,799,924 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.65% | 0.24% | 462,099 | 442,325 | 2236.90% | 13,793,655 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 0.61% | 0.00% | 433,573 | 253,635 | 140.96% | 12,942,154 | Jun 30, 2024 |
Kymera Therapeutics's largest institutional shareholder is PRICE T ROWE ASSOCIATES INC /MD/, holding 9.03% of the company's total share outstanding, currently valued at $190.76M. The top 10 institutional shareholders own together 67.69% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 7.56% | 16.82% | 5,350,422 | -26,940 | -0.50% | 159,710,097 | Jun 30, 2024 |
| AQUILO CAPITAL MANAGEMENT, LLC | 0.46% | 9.46% | 328,743 | -60,000 | -15.43% | 9,812,979 | Jun 30, 2024 |
| BVF INC/IL | 7.29% | 4.32% | 5,161,801 | - | - | 154,079,760 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 2.23% | 2.85% | 1,579,275 | -154,814 | -8.93% | 47,141,359 | Jun 30, 2024 |
| DEER MANAGEMENT CO. LLC | 0.59% | 2.55% | 415,895 | - | - | 12,414,466 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 8.47% | 2.29% | 5,995,928 | - | - | 178,978,451 | Jun 30, 2024 |
| ARTAL GROUP S.A. | 4.25% | 2.29% | 3,005,610 | -21,525 | -0.71% | 89,717,459 | Jun 30, 2024 |
| AVORO CAPITAL ADVISORS LLC | 5.50% | 1.55% | 3,888,888 | - | - | 116,083,307 | Jun 30, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.12% | 1.48% | 82,000 | 82,000 | 100.00% | 2,447,700 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 2.12% | 1.34% | 1,500,000 | 237,754 | 18.84% | 44,775,000 | Jun 30, 2024 |
| PROPEL BIO MANAGEMENT, LLC | 0.08% | 1.09% | 56,359 | - | - | 1,682,316 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.64% | 1.05% | 1,163,973 | -358,265 | -23.54% | 34,744,594 | Jun 30, 2024 |
| NAN FUNG GROUP HOLDINGS LTD | 0.02% | 0.35% | 10,875 | - | - | 324,619 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.07% | 0.29% | 50,626 | 34,626 | 216.41% | 1,511,186 | Jun 30, 2024 |
| ATIKA CAPITAL MANAGEMENT LLC | 0.13% | 0.27% | 92,000 | -10,000 | -9.80% | 2,746,200 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.65% | 0.24% | 462,099 | 442,325 | 2236.90% | 13,793,655 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.73% | 0.15% | 517,797 | 16,867 | 3.37% | 15,456,240 | Jun 30, 2024 |
| E FUND MANAGEMENT CO., LTD. | 0.07% | 0.08% | 48,946 | 38,981 | 391.18% | 1,461,038 | Jun 30, 2024 |
| CAMPBELL & CO INVESTMENT ADVISER LLC | 0.04% | 0.08% | 30,975 | -3,720 | -10.72% | 924,604 | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | 0.04% | 0.07% | 31,011 | -10,321 | -24.97% | 926,000 | Jun 30, 2024 |
The largest Kymera Therapeutics shareholder by % of total assets is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC. The company owns 5.35M shares of Kymera Therapeutics (KYMR), representing 16.82% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BLACKROCK INC. | 5.87% | 0.00% | 4,155,429 | 499,769 | 13.67% | 124,039,557 | Jun 30, 2024 |
| FMR LLC | 6.82% | 0.01% | 4,826,840 | 462,430 | 10.60% | 144,081,174 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.65% | 0.24% | 462,099 | 442,325 | 2236.90% | 13,793,655 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 0.61% | 0.00% | 433,573 | 253,635 | 140.96% | 12,942,154 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 2.12% | 1.34% | 1,500,000 | 237,754 | 18.84% | 44,775,000 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.42% | 0.01% | 295,572 | 227,810 | 336.19% | 8,822,824 | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0.32% | 0.06% | 223,413 | 223,413 | 100.00% | 6,668,878 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.49% | 0.02% | 348,918 | 221,172 | 173.13% | 10,415,202 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.20% | 0.01% | 143,093 | 143,093 | 100.00% | 4,271,326 | Jun 30, 2024 |
| NORGES BANK | 0.17% | 0.00% | 117,883 | 117,883 | 100.00% | 3,518,808 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.49% | 0.00% | 1,054,220 | 88,520 | 9.17% | 31,474,663 | Jun 30, 2024 |
| MORGAN STANLEY | 0.89% | 0.00% | 631,738 | 84,598 | 15.46% | 18,857,400 | Jun 30, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.12% | 1.48% | 82,000 | 82,000 | 100.00% | 2,447,700 | Jun 30, 2024 |
| FIRST TRUST ADVISORS LP | 0.20% | 0.00% | 138,636 | 70,894 | 104.65% | 4,138,284 | Jun 30, 2024 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 0.09% | 0.01% | 64,000 | 64,000 | 100.00% | 1,910,400 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 9.03% | 0.02% | 6,390,658 | 58,646 | 0.93% | 190,763,000 | Jun 30, 2024 |
| VANGUARD GROUP INC | 6.81% | 0.00% | 4,822,416 | 55,366 | 1.16% | 143,949,118 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.57% | 0.00% | 402,385 | 53,176 | 15.23% | 12,012,483 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.20% | 0.00% | 139,788 | 43,793 | 45.62% | 4,172,671 | Jun 30, 2024 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.23% | 0.01% | 162,201 | 41,354 | 34.22% | 4,841,700 | Jun 30, 2024 |
As of Jun 30 2024, Kymera Therapeutics's largest institutional buyer is BLACKROCK INC.. The company purchased 499.77K stocks of KYMR, valued at $124.04M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 2.70% | 0.00% | 1,910,691 | -761,827 | -28.51% | 57,034,126,000 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.06% | 0.00% | 44,944 | -410,992 | -90.14% | 1,341,578 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.64% | 1.05% | 1,163,973 | -358,265 | -23.54% | 34,744,594 | Jun 30, 2024 |
| BARCLAYS PLC | 0.07% | 0.00% | 49,093 | -270,808 | -84.65% | 1,466,000 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.53% | 0.01% | 376,562 | -196,364 | -34.27% | 11,240,376 | Jun 30, 2024 |
| GREAT LAKES ADVISORS, LLC | - | - | - | -156,377 | -100.00% | - | Jun 30, 2024 |
| REDMILE GROUP, LLC | 2.23% | 2.85% | 1,579,275 | -154,814 | -8.93% | 47,141,359 | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.13% | 0.01% | 90,820 | -120,041 | -56.93% | 2,710,977 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.41% | 0.06% | 289,463 | -90,979 | -23.91% | 8,640,469 | Jun 30, 2024 |
| CANDRIAM S.C.A. | 0.34% | 0.04% | 238,165 | -90,137 | -27.46% | 7,108,893 | Jun 30, 2024 |
| UBS GROUP AG | 0.30% | 0.00% | 210,301 | -86,379 | -29.12% | 6,277,485 | Jun 30, 2024 |
| INVESCO LTD. | 0.04% | 0.00% | 29,834 | -83,533 | -73.68% | 890,545 | Jun 30, 2024 |
| AQUILO CAPITAL MANAGEMENT, LLC | 0.46% | 9.46% | 328,743 | -60,000 | -15.43% | 9,812,979 | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | - | - | - | -46,373 | -100.00% | - | Jun 30, 2024 |
| CONGRESS ASSET MANAGEMENT CO /MA | - | - | - | -45,836 | -100.00% | - | Jun 30, 2024 |
| TREXQUANT INVESTMENT LP | 0.17% | 0.05% | 117,328 | -44,787 | -27.63% | 3,502,241 | Jun 30, 2024 |
| AMERICAN CENTURY COMPANIES INC | 0.02% | 0.00% | 10,847 | -36,820 | -77.24% | 323,783 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.03% | 0.00% | 18,286 | -34,766 | -65.53% | 545,837 | Jun 30, 2024 |
| ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 7.56% | 16.82% | 5,350,422 | -26,940 | -0.50% | 159,710,097 | Jun 30, 2024 |
| CAPITAL IMPACT ADVISORS, LLC | - | - | - | -23,889 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Kymera Therapeutics's biggest institutional seller is STATE STREET CORP. The company sold -0.76M shares of KYMR, valued at $57.03B.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0.32% | 0.06% | 223,413 | 223,413 | 100.00% | 6,668,878 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.20% | 0.01% | 143,093 | 143,093 | 100.00% | 4,271,326 | Jun 30, 2024 |
| NORGES BANK | 0.17% | 0.00% | 117,883 | 117,883 | 100.00% | 3,518,808 | Jun 30, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.12% | 1.48% | 82,000 | 82,000 | 100.00% | 2,447,700 | Jun 30, 2024 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 0.09% | 0.01% | 64,000 | 64,000 | 100.00% | 1,910,400 | Jun 30, 2024 |
| CAPITAL FUND MANAGEMENT S.A. | 0.04% | 0.00% | 29,952 | 29,952 | 100.00% | 894,067 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.03% | 0.00% | 24,570 | 24,570 | 100.00% | 734,679 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.03% | 0.00% | 23,931 | 23,931 | 100.00% | 714,340 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.03% | 0.01% | 23,517 | 23,517 | 100.00% | 701,983 | Jun 30, 2024 |
| FRANKLIN RESOURCES INC | 0.03% | 0.00% | 21,793 | 21,793 | 100.00% | 650,521 | Jun 30, 2024 |
| DYNAMIC TECHNOLOGY LAB PRIVATE LTD | 0.02% | 0.05% | 15,471 | 15,471 | 100.00% | 462,000 | Jun 30, 2024 |
| HANDELSBANKEN FONDER AB | 0.02% | 0.00% | 15,400 | 15,400 | 100.00% | 460,000 | Jun 30, 2024 |
| PEAK6 INVESTMENTS LLC | 0.02% | 0.00% | 13,000 | 13,000 | 100.00% | 388,050 | Jun 30, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 0.02% | 0.06% | 10,665 | 10,665 | 100.00% | 318,350 | Jun 30, 2024 |
| STRS OHIO | 0.01% | 0.00% | 9,600 | 9,600 | 100.00% | 286,560,000 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.01% | 0.00% | 9,386 | 9,386 | 100.00% | 280,172 | Jun 30, 2024 |
| VERITION FUND MANAGEMENT LLC | 0.01% | 0.00% | 7,956 | 7,956 | 100.00% | 237,487 | Jun 30, 2024 |
| STATE OF WYOMING | 0.01% | 0.02% | 4,933 | 4,933 | 100.00% | 147,250 | Jun 30, 2024 |
| PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO | 0.01% | 0.00% | 4,672 | 4,672 | 100.00% | 139,000 | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | 0.00% | 0.00% | 2,856 | 2,856 | 100.00% | 84,000 | Jun 30, 2024 |
| RONALD BLUE TRUST, INC. | 0.00% | 0.00% | 278 | 278 | 100.00% | 11,176 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 148 | 148 | 100.00% | 4,418 | Jun 30, 2024 |
| INNEALTA CAPITAL, LLC | 0.00% | 0.00% | 44 | 44 | 100.00% | 1,313 | Jun 30, 2024 |
Kymera Therapeutics's largest new institutional shareholder by number of shares is DRIEHAUS CAPITAL MANAGEMENT LLC, purchased 223.41K shares, valued at $6.67M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| GREAT LAKES ADVISORS, LLC | - | - | - | -156,377 | -100.00% | - | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | - | - | - | -46,373 | -100.00% | - | Jun 30, 2024 |
| CONGRESS ASSET MANAGEMENT CO /MA | - | - | - | -45,836 | -100.00% | - | Jun 30, 2024 |
| CAPITAL IMPACT ADVISORS, LLC | - | - | - | -23,889 | -100.00% | - | Jun 30, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -20,994 | -100.00% | - | Jun 30, 2024 |
| FORA CAPITAL, LLC | - | - | - | -20,343 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -20,095 | -100.00% | - | Jun 30, 2024 |
| Y-INTERCEPT (HONG KONG) LTD | - | - | - | -16,364 | -100.00% | - | Jun 30, 2024 |
| SEVEN EIGHT CAPITAL, LP | - | - | - | -15,963 | -100.00% | - | Jun 30, 2024 |
| BAYESIAN CAPITAL MANAGEMENT, LP | - | - | - | -14,150 | -100.00% | - | Jun 30, 2024 |
| SCIENTECH RESEARCH LLC | - | - | - | -11,572 | -100.00% | - | Jun 30, 2024 |
| NEBULA RESEARCH & DEVELOPMENT LLC | - | - | - | -10,933 | -100.00% | - | Jun 30, 2024 |
| CORTON CAPITAL INC. | - | - | - | -9,951 | -100.00% | - | Jun 30, 2024 |
| GRAHAM CAPITAL MANAGEMENT, L.P. | - | - | - | -7,557 | -100.00% | - | Jun 30, 2024 |
| ROYCE & ASSOCIATES LP | - | - | - | -7,076 | -100.00% | - | Jun 30, 2024 |
| SEI INVESTMENTS CO | - | - | - | -6,930 | -100.00% | - | Jun 30, 2024 |
| INTEGRATED ADVISORS NETWORK LLC | - | - | - | -6,218 | -100.00% | - | Jun 30, 2024 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | - | - | - | -5,911 | -100.00% | - | Jun 30, 2024 |
| PDT PARTNERS, LLC | - | - | - | -5,546 | -100.00% | - | Jun 30, 2024 |
| JGP GLOBAL GESTAO DE RECURSOS LTDA. | - | - | - | -5,183 | -100.00% | - | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | - | - | - | -5,147 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -2,198 | -100.00% | - | Jun 30, 2024 |
| NATIXIS | - | - | - | -1,979 | -100.00% | - | Jun 30, 2024 |
| TRUVESTMENTS CAPITAL LLC | - | - | - | -163 | -100.00% | - | Jun 30, 2024 |
| BENJAMIN F. EDWARDS & COMPANY, INC. | - | - | - | -87 | -100.00% | - | Jun 30, 2024 |
| CONTINUUM ADVISORY, LLC | - | - | - | -13 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -8 | -100.00% | - | Jun 30, 2024 |
| RIGGS ASSET MANAGMENT CO. INC. | - | - | - | -7 | -100.00% | - | Jun 30, 2024 |
| FINANCIAL GRAVITY ASSET MANAGEMENT, INC. | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
Kymera Therapeutics's largest sold out institutional shareholder by shares sold is GREAT LAKES ADVISORS, LLC, sold -0.16M shares, valued at -, as of undefined.
Kymera Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| SPARROW FUNDS | 1.26% | 4,475 | - | - | Feb 29, 2024 |
| Clough Global Equity Fund | 0.87% | 53,955 | - | - | Jan 31, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.60% | 2,986,850 | 232,468 | 8.44% | Mar 31, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.38% | 1,276,841 | 287,207 | 29.02% | Mar 31, 2024 |
| HARTFORD HLS SERIES FUND II INC | 0.28% | 69,043 | - | - | Dec 31, 2023 |
| BlackRock Health Sciences Trust II | 0.27% | 714,476 | - | - | Mar 31, 2024 |
| Clough Global Opportunities Fund | 0.25% | 100,744 | - | - | Jan 31, 2024 |
| Clough Funds Trust | 0.21% | 8,887 | - | - | Jan 31, 2023 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.19% | 596,094 | 206,974 | 53.19% | Mar 31, 2024 |
| PRUDENTIAL SECTOR FUNDS, INC. | 0.11% | 224,924 | 89,285 | 65.83% | Feb 29, 2024 |
| VANGUARD EXPLORER FUND | 0.09% | 1,145,365 | 31,920 | 2.87% | Jan 31, 2024 |
| EntrepreneurShares Series Trust | 0.09% | 23,889 | 23,889 | - | Dec 31, 2023 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.07% | 243,530 | - | - | Mar 31, 2024 |
| ALGER FUNDS | 0.06% | 60,022 | - | - | Jan 31, 2024 |
| WASATCH FUNDS TRUST | 0.06% | 576,917 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.06% | 29,179 | - | - | Mar 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.06% | 1,598,841 | 1,434,737 | 874.29% | Feb 29, 2024 |
| CORNERCAP GROUP OF FUNDS /VA/ | 0.06% | 4,005 | - | - | Sep 30, 2022 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.05% | 404,853 | - | - | Mar 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.04% | 61,045 | 14,211 | 30.34% | Mar 31, 2024 |
| VANGUARD SPECIALIZED FUNDS | 0.04% | 2,027,264 | 585,245 | 40.59% | Jan 31, 2024 |
| Humankind Benefit Corp | 0.04% | 810 | 24 | 3.05% | Dec 31, 2023 |
| AMERICAN CENTURY MUTUAL FUNDS, INC. | 0.02% | 209,705 | - | - | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND IV | 0.02% | 54,000 | - | - | Mar 31, 2024 |
| ROYCE MICRO-CAP TRUST, INC. | 0.01% | 7,076 | -8,928 | -55.79% | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED ALPHADEX FUND | 0.01% | 50,727 | 23,318 | 85.07% | Jan 31, 2024 |
| MFS SERIES TRUST I | 0.01% | 235,728 | -42,797 | -15.37% | Feb 29, 2024 |
| T. Rowe Price Equity Funds, Inc. | 0.01% | 129,514 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 67,881 | -1,747 | -2.51% | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 5,994 | 201 | 3.47% | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 4,183,988 | 75,928 | 1.85% | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 508,826 | -23,487 | -4.41% | Feb 29, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 24,792 | 403 | 1.65% | Feb 29, 2024 |
| NEUBERGER BERMAN EQUITY FUNDS | 0.01% | 62,543 | 62,543 | - | Feb 29, 2024 |
| Nushares ETF Trust | 0.01% | 41,585 | 21,833 | 110.54% | Jan 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.01% | 1,033 | - | - | Mar 28, 2024 |
| DRIEHAUS MUTUAL FUNDS | 0.01% | 47,159 | - | - | Mar 28, 2024 |
| Harbor ETF Trust | 0.00% | 23,129 | -2,719 | -10.52% | Jan 31, 2024 |
| FIDELITY CONTRAFUND | 0.00% | 287,234 | - | - | Mar 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 969 | - | - | Mar 31, 2024 |
| UBS FUNDS | 0.00% | 20,169 | - | - | Mar 31, 2024 |
| ETF Managers Trust | 0.00% | 26,611 | - | - | Dec 31, 2023 |
| North Square Investments Trust | 0.00% | 27,920 | - | - | Jan 31, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 110,184 | 69,833 | 173.06% | Mar 31, 2024 |
| Fidelity Central Investment Portfolios LLC | 0.00% | 130,000 | - | - | Feb 29, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 104,878 | 750 | 0.72% | Jan 31, 2024 |
| MFS VARIABLE INSURANCE TRUST | 0.00% | 69,942 | -11,534 | -14.16% | Mar 31, 2024 |
| ETFis Series Trust I | 0.00% | 3,225 | -612 | -15.95% | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 387,055 | 9,366 | 2.48% | Feb 29, 2024 |
| MML SERIES INVESTMENT FUND | 0.00% | 16,949 | - | - | Dec 31, 2023 |
| VARIABLE INSURANCE PRODUCTS FUND | 0.00% | 34,000 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 4,070 | 295 | 7.81% | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.00% | 13,886 | 13,846 | 34615.00% | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.00% | 9,100 | -270,900 | -96.75% | Jan 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.00% | 11,842 | 11,281 | 2010.87% | Jan 31, 2024 |
| BlackRock ETF Trust | 0.00% | 907 | - | - | Jan 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 30,808 | 4,293 | 16.19% | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 18,562 | -300 | -1.59% | Jan 31, 2024 |
| ProFunds | 0.00% | 11,022 | 3,966 | 56.21% | Mar 31, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 11,999 | -501 | -4.01% | Mar 31, 2023 |
| T. Rowe Price Spectrum Funds II, Inc. | 0.00% | 10,941 | - | - | Feb 29, 2024 |
| Direxion Shares ETF Trust | 0.00% | 115,399 | -2,445 | -2.07% | Jan 31, 2024 |
| BNY MELLON FUNDS TRUST | 0.00% | 50,856 | - | - | Aug 31, 2023 |
| T. Rowe Price Exchange-Traded Funds, Inc. | 0.00% | 4,429 | 1,019 | 29.88% | Mar 31, 2024 |
| NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 63,533 | -26,239 | -29.23% | Mar 31, 2024 |
| Simplify Exchange Traded Funds | 0.00% | 30,515 | - | - | Mar 28, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 12,982 | 369 | 2.93% | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 6,617 | -544 | -7.60% | Mar 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 131,235 | 1,809 | 1.40% | Feb 29, 2024 |
| HARBOR FUNDS | 0.00% | 11,215 | -550 | -4.67% | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND III | 0.00% | 3,800 | - | - | Mar 31, 2024 |
| MFS VARIABLE INSURANCE TRUST III | 0.00% | 7,717 | -315 | -3.92% | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND VI | 0.00% | 2,427 | 2,427 | - | Mar 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 47,124 | 39,851 | 547.93% | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 12,895 | -2,534 | -16.42% | Mar 31, 2024 |
| Fidelity Commonwealth Trust II | 0.00% | 2,668 | - | - | Aug 31, 2023 |
| ETF Series Solutions | 0.00% | 8,658 | 1,386 | 19.06% | Feb 29, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,953 | 63 | 3.33% | Mar 31, 2024 |
| Dimensional ETF Trust | 0.00% | 175,453 | 31,988 | 22.30% | Jan 31, 2024 |
| Global X Funds | 0.00% | 17,463 | 1,177 | 7.23% | Jan 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 209,810 | 6,005 | 2.95% | Feb 29, 2024 |
| DEUTSCHE DWS SECURITIES TRUST | 0.00% | 12,192 | - | - | Jan 31, 2024 |
| Forethought Variable Insurance Trust | 0.00% | 1,410 | - | - | Mar 28, 2024 |
| CLEARWATER INVESTMENT TRUST | 0.00% | 3,024 | -5,160 | -63.05% | Mar 28, 2024 |
| VALIC Co I | 0.00% | 89,308 | 5,919 | 7.10% | Feb 29, 2024 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 1,141 | - | - | Mar 31, 2024 |
| Voya INVESTORS TRUST | 0.00% | 13,894 | - | - | Mar 31, 2024 |
| HARTFORD MUTUAL FUNDS II INC | 0.00% | 39,223 | -82 | -0.21% | Jan 31, 2024 |
| Managed Portfolio Series | 0.00% | 5,306 | - | - | Jan 31, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 19,762 | 1,861 | 10.40% | Jan 31, 2024 |
| HC CAPITAL TRUST | 0.00% | 7,491 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 14,900 | 2,000 | 15.50% | Mar 31, 2024 |
| JPMORGAN TRUST II | 0.00% | 222,320 | - | - | Feb 29, 2024 |
| FIDELITY SECURITIES FUND | 0.00% | 20,501 | -329,428 | -94.14% | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 584 | - | - | Mar 31, 2024 |
| SA FUNDS INVESTMENT TRUST | 0.00% | 3,129 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,356 | 175 | 8.02% | Mar 31, 2024 |
| SEASONS SERIES TRUST | 0.00% | 4,433 | - | - | Mar 31, 2024 |
| RBB FUND, INC. | 0.00% | 16,487 | - | - | Feb 29, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 25,400 | - | - | Feb 29, 2024 |
Kymera Therapeutics's largest mutual fund holder by % of total assets is "SPARROW FUNDS", owning 4.47K shares, compromising 1.26% of its total assets.
Kymera Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 89 | -45.06% |
| 31 Mar, 24 | 162 | 20.00% |
| 31 Dec, 23 | 135 | 11.57% |
| 30 Sep, 23 | 121 | -6.92% |
| 30 Jun, 23 | 130 | - |
| 31 Mar, 23 | 130 | 4.00% |
| 31 Dec, 22 | 125 | 0.81% |
| 30 Sep, 22 | 124 | 25.25% |
| 30 Jun, 22 | 99 | -23.85% |
| 31 Mar, 22 | 130 | -1.52% |
| 31 Dec, 21 | 132 | 10.00% |
| 30 Sep, 21 | 120 | 7.14% |
| 30 Jun, 21 | 112 | 16.67% |
| 31 Mar, 21 | 96 | 28.00% |
| 31 Dec, 20 | 75 | 44.23% |
| 30 Sep, 20 | 52 | - |
As of 30 Jun 24, 89 institutions are holding Kymera Therapeutics's shares, representing a decrease of -45.06% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 25,423,925 | -62.10% |
| 31 Mar, 24 | 67,073,034 | 11.04% |
| 31 Dec, 23 | 60,406,777 | 5.60% |
| 30 Sep, 23 | 57,205,249 | -1.77% |
| 30 Jun, 23 | 58,236,317 | 2.47% |
| 31 Mar, 23 | 56,832,720 | 1.31% |
| 31 Dec, 22 | 56,098,956 | 6.25% |
| 30 Sep, 22 | 52,798,774 | 6.81% |
| 30 Jun, 22 | 49,431,113 | 8.22% |
| 31 Mar, 22 | 45,677,634 | 5.07% |
| 31 Dec, 21 | 43,474,176 | 25.49% |
| 30 Sep, 21 | 34,642,770 | 30.55% |
| 30 Jun, 21 | 26,536,338 | 16.22% |
| 31 Mar, 21 | 22,832,689 | 12.47% |
| 31 Dec, 20 | 20,301,550 | 20.63% |
| 30 Sep, 20 | 16,829,483 | - |
Kymera Therapeutics (KYMR) has 25.42M shares outstanding as of 30 Jun 24, down -62.10% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 35.92% | 0.27% |
| 31 Mar, 24 | 114.92% | 1.07% |
| 31 Dec, 23 | 103.40% | 1.07% |
| 30 Sep, 23 | 98.08% | 0.98% |
| 30 Jun, 23 | 100.08% | 1.05% |
| 31 Mar, 23 | 97.67% | 1.04% |
| 31 Dec, 22 | 96.91% | 1.03% |
| 30 Sep, 22 | 96.82% | 1.06% |
| 30 Jun, 22 | 95.48% | 1.22% |
| 31 Mar, 22 | 88.43% | 1.08% |
| 31 Dec, 21 | 90.59% | 1.94% |
| 30 Sep, 21 | 68.31% | 1.97% |
| 30 Jun, 21 | 58.85% | 2.25% |
| 31 Mar, 21 | 51.14% | 2.45% |
| 31 Dec, 20 | 45.66% | 3.19% |
| 30 Sep, 20 | 37.85% | - |
As of 30 Jun 24, Kymera Therapeutics is held by 35.92% institutional shareholders, representing a 0.27% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 47 | -53.47% |
| 31 Mar, 24 | 101 | 48.53% |
| 31 Dec, 23 | 68 | 11.48% |
| 30 Sep, 23 | 61 | -8.96% |
| 30 Jun, 23 | 67 | 8.06% |
| 31 Mar, 23 | 62 | -10.14% |
| 31 Dec, 22 | 69 | -5.48% |
| 30 Sep, 22 | 73 | 32.73% |
| 30 Jun, 22 | 55 | -31.25% |
| 31 Mar, 22 | 80 | -2.44% |
| 31 Dec, 21 | 82 | -2.38% |
| 30 Sep, 21 | 84 | 2.44% |
| 30 Jun, 21 | 82 | 49.09% |
| 31 Mar, 21 | 55 | 5.77% |
| 31 Dec, 20 | 52 | - |
| 30 Sep, 20 | 52 | - |
47 institutional shareholders have increased their position in KYMR stock as of 30 Jun 24 compared to 101 in the previous quarter (a -53.47% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 27 | -35.71% |
| 31 Mar, 24 | 42 | -17.65% |
| 31 Dec, 23 | 51 | 50.00% |
| 30 Sep, 23 | 34 | 3.03% |
| 30 Jun, 23 | 33 | -21.43% |
| 31 Mar, 23 | 42 | 27.27% |
| 31 Dec, 22 | 33 | 3.13% |
| 30 Sep, 22 | 32 | 6.67% |
| 30 Jun, 22 | 30 | 3.45% |
| 31 Mar, 22 | 29 | 7.41% |
| 31 Dec, 21 | 27 | 17.39% |
| 30 Sep, 21 | 23 | 43.75% |
| 30 Jun, 21 | 16 | -36.00% |
| 31 Mar, 21 | 25 | 92.31% |
| 31 Dec, 20 | 13 | - |
| 30 Sep, 20 | - | - |
27 institutional shareholders have reduced their position in KYMR stock as of 30 Jun 24 compared to 42 in the previous quarter (a -35.71% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 89 | -45.06% | 25,423,925 | -62.10% | 35.92% | 0.27% | 47 | -53.47% | 27 | -35.71% |
| 31 Mar, 24 | 162 | 20.00% | 67,073,034 | 11.04% | 114.92% | 1.07% | 101 | 48.53% | 42 | -17.65% |
| 31 Dec, 23 | 135 | 11.57% | 60,406,777 | 5.60% | 103.40% | 1.07% | 68 | 11.48% | 51 | 50.00% |
| 30 Sep, 23 | 121 | -6.92% | 57,205,249 | -1.77% | 98.08% | 0.98% | 61 | -8.96% | 34 | 3.03% |
| 30 Jun, 23 | 130 | - | 58,236,317 | 2.47% | 100.08% | 1.05% | 67 | 8.06% | 33 | -21.43% |
| 31 Mar, 23 | 130 | 4.00% | 56,832,720 | 1.31% | 97.67% | 1.04% | 62 | -10.14% | 42 | 27.27% |
| 31 Dec, 22 | 125 | 0.81% | 56,098,956 | 6.25% | 96.91% | 1.03% | 69 | -5.48% | 33 | 3.13% |
| 30 Sep, 22 | 124 | 25.25% | 52,798,774 | 6.81% | 96.82% | 1.06% | 73 | 32.73% | 32 | 6.67% |
| 30 Jun, 22 | 99 | -23.85% | 49,431,113 | 8.22% | 95.48% | 1.22% | 55 | -31.25% | 30 | 3.45% |
| 31 Mar, 22 | 130 | -1.52% | 45,677,634 | 5.07% | 88.43% | 1.08% | 80 | -2.44% | 29 | 7.41% |
| 31 Dec, 21 | 132 | 10.00% | 43,474,176 | 25.49% | 90.59% | 1.94% | 82 | -2.38% | 27 | 17.39% |
| 30 Sep, 21 | 120 | 7.14% | 34,642,770 | 30.55% | 68.31% | 1.97% | 84 | 2.44% | 23 | 43.75% |
| 30 Jun, 21 | 112 | 16.67% | 26,536,338 | 16.22% | 58.85% | 2.25% | 82 | 49.09% | 16 | -36.00% |
| 31 Mar, 21 | 96 | 28.00% | 22,832,689 | 12.47% | 51.14% | 2.45% | 55 | 5.77% | 25 | 92.31% |
| 31 Dec, 20 | 75 | 44.23% | 20,301,550 | 20.63% | 45.66% | 3.19% | 52 | - | 13 | - |
| 30 Sep, 20 | 52 | - | 16,829,483 | - | 37.85% | - | 52 | - | - | - |
Kymera Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Kymera Therapeutics's stock was made by Gollob Jared on Jul 16 2024, selling 13,281 shares at $45.59 per share (valued at $605.52K).
Kymera Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 3 | 16 | 18.75% |
| Q2 2024 | 12 | 12 | 100.00% |
| Q1 2024 | 19 | 55 | 34.55% |
| Q4 2023 | 8 | 2 | 400.00% |
| Q3 2023 | 1 | 1 | 100.00% |
| Q2 2023 | 14 | - | - |
| Q1 2023 | 13 | 14 | 92.86% |
| Q4 2022 | 6 | 53 | 11.32% |
| Q3 2022 | 2 | - | - |
| Q2 2022 | 23 | 7 | 328.57% |
| Q1 2022 | 18 | 22 | 81.82% |
| Q4 2021 | 8 | 26 | 30.77% |
| Q3 2021 | 14 | 35 | 40.00% |
| Q2 2021 | 30 | 40 | 75.00% |
| Q1 2021 | 12 | 25 | 48.00% |
| Q3 2020 | 26 | 40 | 65.00% |
3 total buy trades, and 16 total sell trades (buy/sell ratio of 0.19%) were made by Kymera Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 13 | - |
| Q2 2024 | - | 9 | - |
| Q1 2024 | 3 | 49 | 6.12% |
| Q4 2023 | 6 | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | 4 | 14 | 28.57% |
| Q4 2022 | - | 48 | - |
| Q3 2022 | 1 | - | - |
| Q2 2022 | 3 | - | - |
| Q1 2022 | 6 | 14 | 42.86% |
| Q4 2021 | - | 18 | - |
| Q3 2021 | 3 | 22 | 13.64% |
| Q2 2021 | - | 20 | - |
| Q1 2021 | - | 18 | - |
| Q3 2020 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 13 open market sell trades of Kymera Therapeutics's stocks.
Kymera Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| NRIX | Nurix Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| PRLD | Prelude Therapeutics Incorporated |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
KYMR Ownership FAQ
Who Owns Kymera Therapeutics?
Kymera Therapeutics is owned by institutional shareholders (35.92%), insiders (1.28%), and public (62.79%). The largest institutional shareholder of Kymera Therapeutics is PRICE T ROWE ASSOCIATES INC /MD/ (9.03% of total shares) and the top mutual fund owner is SPARROW FUNDS (1.26% of total shares).
Who are the major institutional shareholders of Kymera Therapeutics?
Kymera Therapeutics's major institutional shareholders are PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, BVF INC/IL, and FMR LLC. The top five shareholders own together 39.18% of the company's share outstanding.
How many Kymera Therapeutics shareholders are there?
As of Jun 2024, there are 89 institutional shareholders of Kymera Therapeutics.
What percentage of Kymera Therapeutics is owned by PRICE T ROWE ASSOCIATES INC /MD/?
PRICE T ROWE ASSOCIATES INC /MD/ owns 6.39M shares of Kymera Therapeutics, representing 9.03% of the company's total shares outstanding, valued at $190.76M (as of Jun 2024).
What percentage of Kymera Therapeutics is owned by BAKER BROS. ADVISORS LP?
As of Jun 2024, BAKER BROS. ADVISORS LP holds 6M shares of Kymera Therapeutics (KYMR), compromising 8.47% of the company, valued at $178.98M.
What percentage of Kymera Therapeutics is owned by ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC?
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the third largest holder of Kymera Therapeutics. The company owns 5.35M of the company's shares outstanding (worth $159.71M).